Eighteen months after the European Commission put Teva’s Copaxone marketing practices under a microscope, the walls appear to be closing in on the aging multiple sclerosis blockbuster. Monday, the ...
After eyeing Teva Pharmaceutical Industries for marketing violations for more than a year, the Justice Department decided not to join a False Claims Act case against the compnay. But the ...
Copaxone (glatiramer acetate) may not be safe to receive while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can receive the drug during this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results